15-Year study tracks hidden risks of gene therapy in children
NCT ID NCT02315599
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 7 times
Summary
This study follows 500 children and young adults who received gene therapy for cancer as part of earlier trials. Researchers will monitor them for up to 15 years to detect any delayed side effects. Participants have blood tests and health check-ups at regular intervals. No new treatment is given; the goal is to understand long-term safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- anti-CD19 CAR
- What this could lead to
- If successful, this study will reveal the long-term safety of gene therapy in children, helping future treatments become safer.
- What could go wrong
- This is an observational follow-up study, not a treatment trial. It cannot prove that gene therapy works or is safe for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can specially trained immune cells flush out hidden HIV?
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a Dual-Pronged antibody outsmart advanced solid tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Frailty check may steer safer cancer care for seniors